个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Ye, D.[1] * ; Wang, S.[1] ; Wang, Z.[2,5,6] ; Xing, N.[3] ; Yang, W.[4] ; Wang, Z.[2,5,6] ; Gu, X.[7] ; Zhou, G.[8] ; Sun, Z.[9] ; Guo, J.[10] ; Xue, X.[11] ; Yang, Y.[12] ; Fu, C.[13] ; Wang, C.[14] ; Ding, D.[15] ; Zhang, A.[16] ; Jiang, S.[17] ; Yang, X.[18] ; Lian, J.[19] ; Wang, W.[19] ;
机构： [1]Fudan Univ, Dept Urol, Shanghai Canc Ctr, Shanghai, Peoples R China [2]Nanjing Med Univ, Dept Urol, Affiliated Hosp 1, Nanjing, Peoples R China [3]Chinese Acad Med Sci, Canc Hosp, Dept Urol, Beijing, Peoples R China [4]Hebei Univ, Dept Urol, Affiliated Hosp, Baoding, Peoples R China [5]Lanzhou Univ, Hosp 2, Urol Surg, Lanzhou, Peoples R China [6]Lanzhou Univ, Sch Clin Med, Lanzhou, Peoples R China [7]Jilin Univ, Dept Urol, Bethune Hosp 3, Changchun, Peoples R China [8]Northern Jiangsu Peoples Hosp, Dept Urol, Yangzhou, Jiangsu, Peoples R China [9]Huadong Hosp, Dept Urol, Shanghai, Peoples R China [10]Fudan Univ, Urol Surg, Zhongshan Hosp, Shanghai, Peoples R China [11]Fujian Med Univ, Dept Urol, Affiliated Hosp 1, Fuzhou, Peoples R China [12]Beijing Canc Hosp, Urol Surg, Beijing, Peoples R China [13]Liaoning Canc Hosp & Inst, Dept Urol 2, Shenyang, Peoples R China [14]Jilin Univ, Dept Urol, Bethune Hosp 1, Changchun, Peoples R China [15]Henan Prov Peoples Hosp, Dept Urol, Zhengzhou, Peoples R China [16]Hebei Med Univ, Dept Urol, Hosp 4, Shijiazhuang, Hebei, Peoples R China [17]Hunan Canc Hosp, Urol Surg, Changsha, Peoples R China [18]Jiangsu Hengrui Pharmaceut Co Ltd, Dept Biometr, Shanghai, Peoples R China [19]Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shanghai, Peoples R China
出处：
DOI： 10.1016/j.annonc.2024.08.1730
ISSN：
基金：
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2025]版：
无
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2024]版：
无
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Fudan Univ, Dept Urol, Shanghai Canc Ctr, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Ye D.,Wang S.,Wang Z.,et al.Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial[J].ANNALS OF ONCOLOGY.2024,35:S994-S994.doi:10.1016/j.annonc.2024.08.1730.
APA：
Ye, D.,Wang, S.,Wang, Z.,Xing, N.,Yang, W....&Wang, W..(2024).Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial.ANNALS OF ONCOLOGY,35,
MLA：
Ye, D.,et al."Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial".ANNALS OF ONCOLOGY 35.(2024):S994-S994

资源点击量：15100 今日访问量：0 总访问量：960 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持：重庆聚合科技有限公司 地址：保定市莲池区裕华东路212号